Navigation Links
Eurand's Zentase Effective in Treating Exocrine Pancreatic,Insufficiency, Studies Show

EPI patients in the pivotal study, regardless of disease severity, experienced a clinically significant response to Zentase treatment. Half of these patients had a CFA greater than 90 percent following Zentase treatment and 90 percent of patients had a CFA greater than 79 percent following Zentase treatment. Based on these study findings, Zentase may able to treat all patient types, from those requiring low levels of supplementation to those with severe disease needing high levels of enzyme supplementation.

Pivotal Study Highlights

This randomized, double-blind, placebo-controlled, cross-over study was conducted in 14 CF centers in the US and involved data from 31 patients with EPI. The average age was 15.4 years and the study was evenly split between male and female patients. After open-label dose titration, patients were randomized to receive Zentase or placebo over a week-long period. Following open-label normalization, all patients were crossed over to the alternative treatment arm. A determination of CFA and CNA on a 72-hour sample and under controlled diet in a hospital environment was performed at the end of each randomized treatment arm. No drugs affecting GI motility or pH (eg, PPIs or H2 blockers) were allowed under Zentase treatment.

    -- Direct Dose Response on Improving EPI Symptoms.  Increasing the Zentase

       dose displayed a direct correlation on improving EPI symptoms including

       stool consistency and symptom scores including measures of pain,

       bloating, gas and oil visibility.  A mean increase of 40 percent from

       first to last dose changed the majority of patients from highly

       symptomatic to normal. This was particularly notable for patients with

       abnormal stool at baseline.

    -- Improved Malabsorption Symptoms in Severe EPI Patients.  Response to

       Zentase correlated very well (r> 0.9) with disease severity. Patients

       with more severe malabsorption on placebo (CFA<60 
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Eurand to Present Zentase Phase III Data
2. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
3. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
4. Gabapentin Shown Effective for Fibromyalgia Pain
5. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
6. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
7. XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
8. Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
9. Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
10. Biotheras Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study
11. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
Post Your Comments:
(Date:11/26/2014)... Colo. , Nov. 25, 2014   Heska Corporation ... "Heska" or the "Company"), a provider of advanced veterinary ... Robert Grieve , Executive Chair, will attend The Benchmark ... 2014. The one-on-one conference will be held at The Palmer ... from 8 a.m. to 2:30 p.m. Please email ...
(Date:11/26/2014)... , Nov. 25, 2014  Array ... today announced that its Chief Executive Officer, ... the following upcoming conferences.  The public is ... webcasts on the Array BioPharma website:  ... 3, 2014Time:1:30 p.m.  Eastern Time Location: Palace ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 ... AZN ) today announced that AMAGINE-2 TM , a ... in more than 1,800 patients with moderate-to-severe plaque psoriasis, met ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg given ... each shown to be superior to Stelara on the primary ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... SEOUL, South Korea, Dec. 5, 2011 /PRNewswire-Asia/ -- The ... Industry Development Institute announced that the Health Authority-Abu Dhabi ... National University Hospital, Asian Medical Center and Seoul St. ... a patient treatment-reference system in Abu Dhabi, on Nov. ...
... BEIJING, Dec. 5, 2011 /PRNewswire-Asia/ -- GC-Rise Pharmaceutical Co. ... holds a majority stake, was recently listed as one ... companies which rides on high growth over the past ... women,s health in China, saw its operating revenues rising ...
Cached Medicine Technology:South Korea Signs Accord with Abu Dhabi Health Authority on Hospital Service Agreement 2Women Health Expert GC-Rise Listed in Deloitte's 50 Top-performing Companies 2
(Date:11/27/2014)... By Randy Dotinga ... -- Some people,s brains seem pre-wired to acquire a second ... beyond their mother tongue will likely gain a brain boost, ... connected and integrated after learning," said study co-author Ping Li, ... Pennsylvania State University. But it,s even more interesting, Li said, ...
(Date:11/27/2014)... November 27, 2014 In order to enable ... Sharpes, Fla., designed an easy way to avoid touching a ... He then created a prototype of the patent-pending Toilet Tamer, ... a toilet seat and/or lid in a more sanitary manner. ... spread of germs. Overall, it promotes good hygiene and peace ...
(Date:11/27/2014)... November 27, 2014 Tylenol lawsuits ( ... allegedly injured by the medication are continuing to move ... is looking ahead to a status conference in December, ... Scheduling Order issued earlier this year, a conference in ... at 10:00 a.m. Items likely to be discussed at ...
(Date:11/27/2014)... “LAB.C” was featured on NewsWatch as part ... coolest technology products available to consumers. Mallory Sofastaii, a technology ... and shared with viewers the company offers a cable ... , Consumers love portability and functionality. A unique mobile ... the iPhone5 and 5S has a portable USB charger built ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 HealthPostures, ... office ergonomics equipment , has announced that it ... Commercial Office Environments. The partnership will put HealthPostures' ... furnishings location. , In addition to having its ... dealer partnership promotes HealthPostures' products with the business ...
Breaking Medicine News(10 mins):Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
... the number of seats in existing facilities to fill the ... the central government's proposed quota policy, says Chief Minister Arjun ... medical institutions and open more institutes in the state," said ... doctors and this was the only to "adjust the numbers". ...
... mosquito-transmitted viral fever, has claimed 12 lives in Betul district ... more districts//. ,'With three more deaths Sunday - two ... number of deaths allegedly due to Chikangunya fever in Betul ... here said Thursday. ,'The dead include a 10-year-old ...
... peripheral artery disease (PAD) patients have showed lesser death ... ,Researchers have also indicated that less physically active ... ,‘We found that there is a survival ... active in their daily routines,’ said Mary M. McDermott, ...
... can cause developmental delays in infants whose mothers were ... banned in the United States, officials in Africa plan ... malaria. ,According to study author Brenda Eskenazi, a ... the University of California, Berkeley, the potential benefits of ...
... that vaccines that contain mercury do not increase ... scientists examined patterns between the developmental disorder and ... in the journal Pediatrics. ,Their research ... children given shots after thimerosal, a mercury-based preservative, ...
... the All India Institute of Medical Sciences remained crippled ... to protest the move to sack its Director P ... were closed since last evening as resident doctors and ... apex body headed by Union Health Minister A Ramadoss ...
Cached Medicine News:Health News:Chikungunya Death Toll Raises to 12 in Madhya Pradesh 2Health News:Physical Activity benefited Peripheral Artery Disease (PAD) patients 2Health News:Developmental Delays in Infants Linked to DDT 2
... This stool is unquestionably the finest operating ... especially for the ophthalmic surgeon who must ... A poor stool can unexpectedly shift resulting in ... solid base of five sturdy casters. A "foot ...
This is a 2.5x focusing Galilean telescope with a range from 70cm to infinity. Ideal for use at sporting events, as well as for a wide range of hobbies....
This 6x or 8x aspheric magnifier is fitted with a distance piece and is particularly useful for patients with tremor or focusing difficulties. The magnifier can be either spectacle mounted or hand h...
All Keeler magnifiers and telescope are available on a clip to fit over the patient's own spectacle...
Medicine Products: